An international syndicate of investors comprised of venBio, Amgen, Aisling Capital and Abingworth has invested up to CHF 37m in equity and debt in Swiss biotech company Cytos Biotechnology Ltd.
Target Global I closed on €300m in 2015 and is now fully deployed
Existing investor Redalpine also participates in the round for the online ticketing platform
Deal is Sortera's 13th acquisition since it was established in 2006
Alpina began its ERP software buy-and-build platform with the acquisition of Oxaion in 2015